Progress has been made recently in developing antibody-drug conjugates (ADCs) that can
selectively deliver cancer drugs to tumor cells. In principle, the idea is simple: by attaching …

Simple Summary Antibody-Drug Conjugates (ADCs) provide effective anti-cancer
treatments. ADC development requires the identification of appropriate tumour-associated …

Antibody-drug conjugates utilize the antibody as a delivery vehicle for highly potent cytotoxic
molecules with specificity for tumor-associated antigens for cancer therapy. Critical …

Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the
potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic …

Biological therapies play an increasing role in cancer treatment, although the number of
naked antibodies showing clinical efficacy as single agent remains limited. One way to …

Target selection for antibody–drug conjugates (ADC) frequently focuses on identifying
antigens with differential expression in tumor and normal tissue, to mitigate the risk of on …

Since the advent of hybridoma technology, dating back to 1975, monoclonal antibodies
have become an irreplaceable diagnostic and therapeutic tool for a wide array of human …

Introduction: CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL),
anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It …

Induced pluripotent stem cells (iPSCs) are promising candidate cells for cardiomyogenesis
in the failing heart. However, teratoma/tumour formation originating from undifferentiated …

Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive mature NK/T-cell
neoplasm marked by NK-cell phenotypic expression of CD3ε and CD56. While the disease …